Research on Single-cell Sequencing of Tumor Stem cells in the Nano-Targeting of Triple-Negative Breast Cancer
DOI:
https://doi.org/10.61173/ccer2m62Keywords:
-Cancer stem cells, single-cell sequencing, tumor heterogeneity, nanomedicine, triple-negative breast cancerAbstract
Primarily attributed to its profound intratumoral heterogeneity and the lack of actionable molecular targets for therapy, triple-negative breast cancer (TNBC) exhibits the most unfavorable clinical treatment prognosis. In recent years, the emergence of single-cell sequencing (SCS) technology has provided unprecedented resolution for analyzing the internal heterogeneity of TNBC, especially showing unique advantages in analyzing the heterogeneity of tumor stem cells (CSCs). At the same time, the development of nanotechnology has provided new opportunities for targeted therapy of CSCs. Nanotargeted drugs based on the key targets identified by SCS have shown good potential in anti-resistance and anti-metastasis in preclinical studies. However, the dynamics of the tumor microenvironment, the immunogenicity of nanomaterials, and individual molecular differences remain significant challenges currently. Future research should focus on the dynamic monitoring function of SCS and the optimization of the biocompatibility of the nanomedicine delivery system to achieve the clinical translation of individualized treatment strategies.
References
[1] P. Zagami and L. A. Carey, “Triple negative breast cancer: Pitfalls and progress,” npj Breast Cancer, vol. 8, p. 95, 2022.
[2] M. Li, T. Yan, M. Wang, Y. Cai, and Y. Wei, “Advances in single-cell sequencing technology and its applications in triplenegative breast cancer,” Breast Cancer (Dove Med Press), vol. 14, pp. 465–474, 2022.
[3] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proc. Natl. Acad. Sci. U.S.A., vol. 100, no. 7, pp. 3983–3988, 2003.
[4] K. L. Lee, Y. C. Kuo, Y. S. Ho, and Y. H. Huang, “Triplenegative breast cancer: Current understanding and future therapeutic breakthrough targeting cancer stemness,” Cancers (Basel), vol. 11, no. 9, p. 1334, 2019.
[5] T. D. King, M. J. Suto, and Y. Li, “The Wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer,” J. Cell Biochem., vol. 113, no. 1, pp. 13–18, 2012.
[6] S. Wu, Q. Tang, W. Fang, Z. Sun, M. Zhang, E. Liu, Y. Cao, and Y. Huang, “Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery,” Acta Pharm. Sin. B, 2025.
[7] S. J. Conley, E. Gheordunescu, P. Kakarala, B. Newman, H. Korkaya, A. N. Heath, S. G. Clouthier, and M. S. Wicha, “Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia,” Proc. Natl. Acad. Sci. U.S.A., vol. 109, no. 8, pp. 2784–2789, 2012.
[8] F. Tang, C. Barbacioru, Y. Wang, E. Nordman, C. Lee, N. Xu, X. Wang, J. Bodeau, B. B. Tuch, A. Siddiqui, K. Lao, and M. A. Surani, “mRNA-Seq whole-transcriptome analysis of a single cell,” Nat. Methods, vol. 6, no. 5, pp. 377–382, 2009.
[9] P. Bhat-Nakshatri, H. Gao, A. S. Khatpe, et al., “Singlenucleus chromatin accessibility and transcriptomic map of breast tissues of women of diverse genetic ancestry,” Nat. Med., vol. 30, pp. 3482–3494, 2024.
[10] S. Z. Wu, D. L. Roden, C. Wang, et al., “Stromal cell diversity associated with immune evasion in human triplenegative breast cancer,” EMBO J., vol. 39, no. 19, p. e104063, 2020.
[11] M. Karaayvaz, S. Cristea, S. M. Gillespie, et al., “Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq,” Nat. Commun., vol. 9, no. 1, p. 3588, 2018.
[12] C. Kim, R. Gao, E. Sei, et al., “Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing,” Cell, vol. 173, no. 4, pp. 879–893.e13, 2018.
[13] M. W. Lee, F. J. Lopez-Diaz, S. Y. Khan, M. A. Tariq, Y. Dayn, C. J. Vaske, A. J. Radenbaugh, H. J. Kim, B. M. Emerson, and N. Pourmand, “Single-cell analyses of transcriptional Dean&Francis ISSN 2959-409X heterogeneity during drug tolerance transition in cancer cells by RNA sequencing,” Proc. Natl. Acad. Sci. U.S.A., vol. 111, no. 44, pp. E4726–E4735, 2014.
[14] S. Wu, Q. Tang, W. Fang, Z. Sun, M. Zhang, E. Liu, Y. Cao, and Y. Huang, “Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery,” Acta Pharm. Sin. B, 2025.
[15] R. Yang, M. Lu, L. Ming, Y. Chen, K. Cheng, J. Zhou, et al., “89Zr-labeled multifunctional liposomes conjugate chitosan for PET-trackable triple-negative breast cancer stem cell targeted therapy,” Int. J. Nanomedicine, vol. 15, pp. 9061–9074, 2020.
[16] N. G. Nabil, R. Alzhrani, H. O. Alsaab, M. Atef, S. Sau, A. K. Iyer, and H. E. Banna, “CD44 targeted nanomaterials for treatment of triple-negative breast cancer,” Cancers (Basel), vol. 13, no. 4, p. 898, 2021.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
